Press release
Aplastic Anemia Market Growth to Surge During Forecast Period (2024-2034), Says DelveInsight
To Know in detail about the Aplastic Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aplastic Anemia Market Forecast
https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Aplastic Anemia Market Report:
• The Aplastic Anemia market size was valued approximately USD 270 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In September 2025, Omidubicel is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy sourced from cord blood. Marketed as Omisirge®, it is approved for adults and pediatric patients aged 12 and older with hematologic malignancies who are scheduled for umbilical cord blood transplantation following myeloablative conditioning, aiming to shorten neutrophil recovery time and lower the risk of infection.
• Japan holds the position of the second-largest market for aplastic anemia among the 7MM. In 2023, the market size for aplastic anemia in Japan was approximately USD 35 million and is anticipated to grow during the forecast period.
• Throughout the forecast period, the increase in the aplastic anemia market size is expected to be driven by pipeline candidates like Omidubicel-onlv, REGN7257, and ALVAIZ (eltrombopag choline).
• In 2023, Germany holds the largest market size among the EU4 and the UK, with approximately USD 14 million, followed by France.
• In 2023, around 56% of aplastic anemia cases in the 7MM were reported in individuals aged 60 and above, with the remaining 43% occurring in those under 60.
• In the EU4 nations, Germany had the highest estimated incident cases of aplastic anemia, comprising approximately [insert percentage here].
• Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others
• Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others
• The Aplastic Anemia epidemiology based on gender analyzed that the male-to-female ratio is approximately 1:1
• The Aplastic Anemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Aplastic Anemia pipeline products will significantly revolutionize the Aplastic Anemia market dynamics.
Aplastic Anemia Overview
According to the National Institutes of Health, pancytopenia and decreased or nonexistent hematopoietic precursors in the bone marrow are symptoms of aplastic anaemia, which is a state of chronic primary hematopoietic failure brought on by damage.
Get a Free sample for the Aplastic Anemia Market Report
https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Aplastic Anemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Aplastic Anemia Epidemiology Segmentation:
The Aplastic Anemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Aplastic Anemia
• Prevalent Cases of Aplastic Anemia by severity
• Gender-specific Prevalence of Aplastic Anemia
• Diagnosed Cases of Episodic and Chronic Aplastic Anemia
Download the report to understand which factors are driving Aplastic Anemia epidemiology trends @ Aplastic Anemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Aplastic Anemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Aplastic Anemia market or expected to get launched during the study period. The analysis covers Aplastic Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Aplastic Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Aplastic Anemia Therapies and Key Companies
• ALVAIZ (eltrombopag choline): Teva Pharmaceuticals
• REGN7257: Regeneron Pharmaceuticals
• PF-06462700: Pfizer
• Omidubicel: Gamida-Cell
• Romiplostim: Kyowa Kirin
• Eltrombopag: Novartis
• AMG531: Kyowa Kirin
• Eltrombopag: Novartis
• Hetrombopag Olamine: Jiangsu HengRui Medicine Co., Ltd.
• Ibrutinib: Janssen Scientific Affairs, LLC
Discover more about therapies set to grab major Aplastic Anemia market share @ Aplastic Anemia Treatment Market
https://www.delveinsight.com/sample-request/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Aplastic Anemia Market Strengths
• Aplastic Anemia (AATD) is a complex disorder, efforts have been made by researchers and scientific professionals to improve the understanding of the pathogenesis and diagnosis of this condition
• Treatment of AATD has improved significantly in recent years with the availability of several safe and effective therapies. Several consensus guidelines have been created to further assist in the management of patients
Aplastic Anemia Market Unmet Needs
• Need of novel and effective treatment for Aplastic Anemia
• Need to develop management guidelines for patients with Aplastic Anemia
• Need for reassessment of doses for Aplastic Anemia
Scope of the Aplastic Anemia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others
• Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others
• Aplastic Anemia Therapeutic Assessment: Aplastic Anemia current marketed and Aplastic Anemia emerging therapies
• Aplastic Anemia Market Dynamics: Aplastic Anemia market drivers and Aplastic Anemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Aplastic Anemia Unmet Needs, KOL's views, Analyst's views, Aplastic Anemia Market Access and Reimbursement
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aplastic Anemia Market Growth to Surge During Forecast Period (2024-2034), Says DelveInsight here
News-ID: 4202827 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Aplastic
Acquired Aplastic Anemia Market: Growth Trends to Watch
Acquired Aplastic Anemia Market valued at USD X.X Billion in 2024 and is projected to reach USD X.X Billion by 2032, growing at a CAGR of X.X% from 2025 to 2032.
What is the Acquired Aplastic Anemia Market and Why is It Significant?
The Acquired Aplastic Anemia market refers to the segment of healthcare focused on diagnosing, treating, and managing acquired aplastic anemia, a rare blood disorder where the bone marrow fails…
Strategic Partnerships Drive Advancements In Aplastic Anemia Treatment And Resea …
How Are the key drivers contributing to the expansion of the aplastic anemia market?
The escalating expenses on healthcare are anticipated to stimulate the aplastic anemia market's expansion in the future. This growth in healthcare spending is mainly attributed to factors like aging populations and rising chronic illnesses that necessitate expensive treatments. Investments in healthcare facilitate treatments for aplastic anemia by providing funds for specialized medical institutions, innovative therapies, and research…
Leading Element Driving Change in the Aplastic Anemia Market in 2025: Impact Of …
What Is the Estimated Market Size and Growth Rate for the Aplastic Anemia Market?
The market size of aplastic anemia has seen considerable growth in past years. There is expected growth from $6.63 billion in 2024 to $7.03 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The historic growth of this market can be credited to several factors, including a rise in the incidence of blood disorders,…
Aplastic Anemia Market: A Growing Need for Treatment
The aplastic anemia market has witnessed significant growth in recent years, driven by advancements in medical technology, increasing awareness of the condition, and the desire for effective treatment options. This post will delve into the market, exploring its size, share, opportunities, challenges, demand, and trends.
Market Size and Share
The aplastic anemia market is a substantial segment of the global hematology and oncology industry. While precise figures can vary depending on data…
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435
This latest report researches the industry structure,…
Global Acquired Aplastic Anemia Market Insights, Forecast
Acquired aplastic anemia is a rare, serious blood disorder, due to failure of the bone marrow failure to produce blood cells. Bone marrow is the spongy substance found in the center of the bones of the body, in adults mainly the spine, pelvis, and large bones of the legs. The global Acquired Aplastic Anemia market is valued at xx million US$ in 2018 and will reach xx million US$ by…
